Dr Tarantino On The Safety Of T-Dxd And T-Dm1 In Her2+ Breast Cancer

Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer

Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

Evaluating the safety of T-DXd with radiotherapy in HER2+ metastatic breast cancer

Comparing and sequencing T-DM1 and T-DXd in HER2+ breast cancer

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer

TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasis

DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer

DESTINY-Breast02: high levels of efficacy of T-DXd in previously treated HER2+ breast cancer

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previo...

Choosing between tucatinib and T-DXd in HER2+ breast cancer

T-DXd; DS-8201a in subjects with HER2-positive metastatic breast cancer previously treated with ...

DESTINY-Breast04: T-DXd for patients with HER2-low mBC

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer

Dr. Tripathy on Trastuzumab Deruxtecan Versus T-DM1 in HER2-Expressing Breast Cancers

Benefit of Antibody Drug Conjugate T-DM1 in HER2+ BC

Targeted Oncology

Sequencing HER2-targeted therapies in breast cancer